outperform
reason report
d/g mp cyno still overhang nt ep upsid potenti
limit pt
bottom line downgrad mp op
lower pt vs convict near-term ep
estim upsid diminish -- -especi tax-benefit-
relat ep cushion basic get use mitig
reduc sale outlook lower cyno expect
cyno compani achil heel sinc acq close
begin question whether busi
struggl might structur natur vs pure sale forc
execution/backfil management assum meanwhil still declin
gyn franchis also turnaround time uncertain slow
us molecular growth ex-blood screen revenue add grow set
headwinds/uncertainti ultim view tough end-
market thu move mp rate pend greater confid
ep upsid potenti cyno number begin move
need come and/or organ cc revenue growth
sustain move back msd territori faster-than expect
lower estim pt vs follow result
lower sale outlook expect price-to-earnings multipl could
compress w/share indic
aftermarket appli lower vs
prior get us appreci stock cheap p/
 discount peer also think share could remain range-bound
given lower confid ep upsid potenti slow sale
growth outlook ultim think under-perform segment
cyno gyn also still declin could continu serv
extend stock overhang limit near-term opportun multipl
cyno forecast slightli conserv assumpt molecular
gyn ep decreas forecast
move lower project lower overal sale less cyno
ep contribut vs prior accret estim higher level
op-ex spend requir re-acceler cyno sale growth
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
compani inform leerink partner llc research
revenu mm
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
sale slightli ahead expect best qualiti
 help distributor acquisit bh ep come
in-lin margin under-perform sale compar
consensu driven mostli breast health bh sale upsid --
help distributor acquisit grew y/i cc
diagnost ex-blood screen miss expect impact
weather flu jan -feb though management indic march trend
blood screen enabl total diagnost divis come in-
line lower qualiti medic aesthet cyno miss consensu
season weaker quarter -- -mark anoth cyno miss
gyn though roughli in-lin continu declin y/i y/i cc
myosur acceler vs estimate off-set
erod novasur revenue vs estimate perform gm
came think op margin shi
expect lower share count ad ultim ep
came in-lin
revenue growth outlook decreas primarili cyno
turnaround go take longer origin anticip cyno
primari reason management sale outlook reduct
cyno result miss street forecast disappoint
terribl howev management took write busi
compani growth project vs origin expect
time deal re-set lower well management longer confid
ramp busi expect cyno declin
substanti y/i versu prior expect pro-forma growth
ultim updat cyno growth outlook result new
report revenue growth rang vs prior revenue
growth translat rang cc growth lsd org cc
growth organ cc sell day adj basi move
forecast vs org cc sell day adj growth prior
think turnaround cyno could take longer-than
project there guarante management lower/upd cyno
outlook right project proven move
target almost qtr row light management commentari around
cyno busi stronger today point
sinc acquisit unusu amount churn us sale
forc rebuild obviou setback clear
compani cyno busi abl meet
origin revenue goal contempl deal model
us sale forc hire rep new last year --
mani hire within last day need
right senior management place ad new rep
aggress train rep take rep month get
fulli speed us suggest rep contribut
meaning busi re-acceler beyond
ep guidanc reiter despit reduc sale outlook
think upward ep revis limit management feel confid
abil control expens addit multipl way drive
leverag within prompt reiter adj
ep outlook rang y/i report
management take oppti make invest result tax
rate reduct earlier year vs prior
manag take opex reduct compar
prior guidanc compani decid scale back
invest plan bake guidanc result tax rate
reduct initi gave ep guidanc --
assum full tax-benefit would flow-through bottom-lin
part model ep
rate share market perform pt convict near-term ep estim
upsid diminish -- -especi tax-benefit- relat ep cushion
basic get use mitig reduc sale outlook lower cyno
expect cyno compani achil heel sinc acq close
begin question whether busi struggl might structur natur
vs pure sale forc execution/backfil management assum meanwhil still declin
gyn franchis also turnaround time uncertain slow us molecular growth
ex-blood screen revenue add grow set headwinds/uncertainti ultim view
tough end-market thu move mp rate pend greater confid ep
upsid potenti cyno number begin move need come
and/or organ cc revenue growth sustain move back msd territori faster-than
price target vs prior base multipl forward
price-to-earnings multipl current appli ep follow result
lower sale outlook expect price-to-earnings multipl could compress
w/share indic aftermarket appli lower
vs prior get us appreci stock cheap price-to-earnings discount
peer also think share could remain range-bound given lower confid ep upsid
potenti slow sale growth outlook ultim think under-perform segment
cyno gyn also still declin could continu serv extend stock
overhang limit near-term opportun multipl expans
peer group use blend select med-tech capit equipment/imag
comp group current trade averag forward price-to-earnings multipl
current trade
ev/ebitda basi trade peer group average
pt would impli ebitda roughli in-lin holx
current forward multipl group forward average
risk valuat includ us hospit administr pull back capital-expenditure
invest could caus delay holx capital-expos busi within breast health
tomo affirm unabl execut cost-synergi goal -- -or cyno integr
effort gener prove challeng expect -- -thi could make harder
achiev sale growth ep accret assumpt thu ep estim
enough increment growth tailwind off-set eventu slowdown beyond
tomo cycl could put out-year estim risk
dollar million except ep
leerink partner llc research streetaccount consensu compani report
dollar million except ep
margin sale
compani report leerink partner llc estim
organ cc growth low-
organ growth
ex-cyno ex-b
expand faster
organ growth
greater
adj fewer sell day
non-recur
royalti revenue
organ cc growth mid-
organ growth
ex-cyno ex-b
expand faster
lower
organ growth
greater
relat bs gaap
relat bs gaap
adj fewer sell day
non-recur
adj fewer sell day
non-recur
royalti revenue
organ cc growth mid-
organ growth
ex-cyno ex-b
expand faster
adj fewer sell day
non-recur
royalti revenue
organ growth
greater
adj fewer sell day
non-recur
leerink partner llc compani report
adj non-gaap gross profit ex-amort
adj non-gaap incom oper ex-amort
incom incom tax
provis incom tax
adj non-gaap net incom ex-amort
adj non-gaap ep ex-amort dilut
compani report leerink partner estim
exclud japanes red cross stock
growth yoy ex-jrc stock
